Esperion Therapeutics, Inc.
corporate_fare Company Profile
Esperion Therapeutics, Inc. (NASDAQ:ESPR) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 26 items for ESPR at importance 7 or higher on its 1–10 market-impact scale.
Recent high-impact activity:
- Esperion Therapeutics Reports Strong 2025 Revenue Growth, Reduced Loss, Confirms Corstasis Acquisition, But Faces Material Weakness in Internal Controls
- Esperion Reports Strong Q4 Revenue & Profit, Secures Key Patent Exclusivity to 2040
- Esperion Therapeutics Projects 2026 Operating Expenses Between $225M and $255M
- Esperion to Acquire Corstasis Therapeutics for $75M Upfront, Expanding Cardiovascular Franchise with FDA-Approved Enbumyst
- Esperion to Acquire Corstasis, Expanding Cardiovascular Franchise with Enbumyst(TM)
Financial Snapshot
Fiscal year ended December 31, 2025
Revenue
$403.13M
Net Income
-$22.68M
Diluted EPS
-$0.11
Op. Cash Flow
-$13.09M
Free Cash Flow
-$13.09M
Operating Income
$60.27M
Cash & Equivalents
$167.85M
Debt / Equity
0.00×
Net Margin
-5.6%
Shares Outstanding
207.87M sh
Source: 10-K · filed 2026-03-10 · accession 0001628280-26-016522